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Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of 
gastrointestinal system and they are characterised by extreme variability in clinical, 
hystopathological and genetic features. It is considered that all GISToms have a malignant 
potential. Ethiological factors which cause GISToms have not been clarified yet, and 
genetic basis is not easy to be determined since GISToms are mostly sporadic. However, 
certain genetic and cytogenetic aberations which have been determined can be considered 
to have an impact on the onset of GISToms. Macroscopic picture is polymorphic, but they 
can most frequently be seen as large, mushroom-like, intraluminal, clearly limited pseudo-
incapsulated submucosal masses. Hystomorphology of these tumors shows a high spectar 
of structural and cellular variations. They are most frequently built out of spindle cells (60-
70% of cases), rarely of epitheloid (about 30% of cases) and very rarely of mixed and 
transitional type (intermedial). Stroma is predominantly loose or poorly colagenized with 
neoangiogenesis, which is markedly in GISToms with a higher malignant potential. Most of 
GISToms (95%) express transmembrane receptors KIT (CD 117), CD 34, vimentine, 
specific neurogenic and smooth muscle cells markers. The most successful therapies are: 
surgical ressection, imatinib and sunitinib (in case of imatinib resistence) therapy (tyrosine 
kinase receptor blockers). Research are being conducted all over the world with the aim of 
finding new and more efficient drug therapies that would not manifest resistency. Acta 
Medica Medianae 2010;49(3):58-64. 
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Introduction 
 
Gastrointestinal stromal tumors (GISTs) 
are the most common mesenchimal tumors of 
gastrointestinal system. Their apperance is chara-
cteristic of the male population. Even if they can 
be found in patients of all ages, it is often 
diagnosed in patients between the age of 40 and 
80. GISTs used to be poorly defined tumors, 
resistant to therapy, but with the help of science 
progress they have become well-defined tumors 
that are possible to treat. They are characterised 
by extreme diversity in clinical, hystopathological 
and genetic characteristics. They gained in their 
importance since they became a real model for 
successful molecular therapy of tumors (1). They 
are very rare (their frequency of occurence is 10 
to 20 cases per million residents in western 
countries); however, GISTs account for 1-3% of 
all the gastrointestinal neoplasms and about 5% 
of sarcomas of all soft tissues (2-4). It is believed 
that all GISTs have malignant potential, although 
small GISTs (diameter up to 1cm) have benign 
biological potential and micromorphology in high 
percent of cases (5,6). About 60-70% of GISTs 
occus in the stomach, 20-30% in the small 
intestine and 5% in colon and rectum and even 
esophagus. Rarely GISTs can develop in omentum, 
mesentery or even retroperitoeally (1,7).  
 
Ethiology of GISTs 
 
Ethiological factors that cause GISTs are 
not clearly defined, and their genetic basis is 
difficult to be determined since they are mostly 
sporadic. There are only a few cases in which 
GISTs have occured in more than one member in 
a family. About 85% of stromal tumors express 
mutation in exon 9, 11, 13, 17 in KIT proto-
oncogen which codes c-Kit (CD117), a tirosin 
kinase receptor, while 3-18% express a mutation 
in exons 12, 14 and 18 on the platelet derived 
growth factor receptor alpha (PDGFRA) gene 
which codes PDGFRA. It is believed that interstitial Acta Medica Medianae 2010, Vol.49(3)                              Morphological and immunocytochemical characteristics of stromal… 
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Cahal cells (ICC) extremely express KIT and that 
the loss of KIT receptor has a consequence of 
losing ICC function. No mutations were have 
been found in 5% of cases and it has been 
sugested that mutations are not always responsible 
for histogenesis of GISTs (2,3,8).  
It is pointed out that cytogenetical aberations 
that involve the loss of 1p, 13q, 14q or 15q, loss 
of heteosigosity of 22q, numerical chromosomal 
aberations (monosomy of chromosome 14, mono-
somy of chromosome 22) and instability of 
nuclear and mitochondrial microsatelites are 
responsible for occurence of GISTs. Molecular 
genetic aberations include loss of p16 (INK4A) 
and p14 (ARF) heterozygocity, p15 metilation 
(INK4B), homozygous loss of Hox 11L1 gene and 
amplification of CMYC, MDM2, EGFR1 and CCND1 
(9,10,11).  
According to latest research, type of 
mutation is a key point for the occurrence, 
development and progression of disease, and 
specific mutations on KIT gene contribute to a 
worse prognosis of GIST (12,13). Mutations in c-
kit gene can lead to a familial GIST syndrome, 
when GISTs occur in a much earlier age than 
usual. Difference between this syndrome and 
sporadic GISTs is that we can find the inherited 
mutation in every cell of organism and not only in 
cancer cells. We can very rarely find a mutation 
of PDGFRA gene in the etiology of this syndrome. 
Skin stains that are similar to those characteristic 
for neurofibromatosis (caffee-au-lait) can be 
found on the skin of the patients with familial 
GIST syndrome, so these patients used to be 
mistreated until tumor markers were developed. 
An increased risk for development of GIST has 
been noticed in patients that suffer from 
neurofibromatosis which is a consequence of NF-
1 gene mutation. Occurrence of this tumor was 
also noticed as a part of Carneys triad (gastric 
GIST, paraganglioma and lung chondrom) (1). 
GISTs develop from ICC that are scattered 
around myenteric plexus, between circular and 
longitudinal muscle layer. They function as 
intestinal pacemaker cells that regulate motility 
of intestines. They have spindle or radial shape, 
and if the tumor exists they are larger with 
abundant cytoplasm and hyperchromatic large 
nucleus with prominent nucleolus (14,15). 
 
Macroscopic appearance of GISTs 
 
Macroscopic appearance of GISTs is 
polymorphic: most frequently they appear as 
large, mushroom-like, intraluminal, clearly limited 
pseudoincapsulated submucosal masses. Mucose is 
intact or with numerous erosions or ulcerations 
(Figure 1a). Solid nodular sarcomatoid structure is 
evident on the intersection field, with spots of 
hemorrhage, necrosis or with pseudocysts of 
different size that are giving them specific and at 
the same time distinctive appearance (Figure 
1b). They rarely appear as large tumor masses 
that fill in the whole stomach lumen, thereby 
gaining its shape and turning its wall into the 
cystic diverticuloid structure, without infiltration 
except in the part where it emerges from depth 
when they are massive, necrotic-haemorrhagic 
and sarcomatoid (Figure 2a). Large dimensions 
and large lumen of stomach let them gain a relief 
and sculptural appearance of white marble when 
numerous spherical and band-like structures 
interlace (Figure 2b). Sometimes they imitate 
leiomyomas because of intramural localization, 
nodular appearance and extreme strength, especially 
if they are small (Figure 2c). And those of 
subserosal localization turn to abdomen and 
thereby gain a size that is sometimes even larger 
than 20cm, but they are very rare. The smallest 
(<1cm in diameter), asymptomatic, intramural or 
subserosal can be discovered only by chance 
during surgical interventions of different kind, 
ultrasound endoscopy or autopsy. When they are 
found in small intestine they are macroscopically 
hard to differ from stomach GISTs, except for 
frequent local wall widening, reminding us of 
diverticules. In colon they appear as sparsely, 
polypoid, submucosal and of harder consistence, 
with rare field of necrosa and hemorrhage. 
 
 
 
Figure 1. a) Mushroom-like appearance with 
pseudocapsule in the lower half and multiple ulcerations of 
mucosa (arrows) b) Characteristics of GISTs on section. 
Nodular compact structure with fields of haemorrhage 
(arrow pointing to the right), necrosis (arrow pointing to 
the left) and with cysts generation (arrow pointing up). Morphological and immunocytochemical characteristics of stromal…                                                                     Vuka Katić et al. 
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Figure 2 a) Compressive atrophy of the whole gastric 
wall with semissesile GIST. b) Irregular relief 
appearance of GIST, colored white. 2c) Intraoperative 
finding. Intramural localization of GIST with field of 
hemorrhage on section places. 
 
Microscopic characteristics 
 
Histomorphology of these tumors shows a 
high range of structural and cellular variations. 
They are most frequently built out of spindle cells 
(60-70% of cases, rarely of epitheloid (about 
30% of cases), mixed and intermedial. Disposition 
of cells can be palisad, fascicular, meandering, 
nest-like, roseta-like or even compact and 
without any scheme and rule of disposition. 
Patohistologically spherical or giant cells can be 
seen and significant infiltration with mononuclears 
is rarely present (16). In the so called „classical 
presentation“ with spindle cells, GIST is chara-
cterised with relatively monomorphic and homo-
genous distribution of cells whose borders are 
unclear and whose cytoplasm is pale eosinophilic. 
Nuclei are spindle or ovoid, with clear boundaries 
and unequally distribued chromatine. Sometimes, 
notched or lobular nuclei can be seen. Pleo-
morphism, polynuclearism and perripheral position 
of nuclei are rare, but it is possible to notice 
vacuolisation, nucleolysis or hyper-chromasia. 
Sometimes nuclei are palisad and sometimes 
semiorganoid layout of tumor cells is present. 
Colagenous matrix and fields of calci-fications are 
very rare (6,17-20). In the case of malignant 
presentation a high grade of cellularity is 
dominant with pleomorphic cythological and 
nulear characteristics (19,21). Epitheloid type of 
GIST is characterised by irregular nest-like 
organisation of cells, with frequent changes in 
stroma and variable celularity (Figure 3a). Cells 
show a less frequent equability, that is, it is 
possible to see a range of transitional forms – 
small round, poligonal, irregular, elongated and 
large pleomorphic forms. Cytoplasm is eosinophilic 
to dark eosinophilic and granular. Light cell 
epitheloid type is usually a consequence of 
vacuolisation in cytoplasm, so cells often gain a 
shape of a sinet ring which makes problems in 
diagnostics. Since this change cannot be seen on 
frozen preparations, it is assumed that it is an 
artefact that occured as a consequence of 
formalin fixation (19,22,23). Rare cytomorpho-
logic types are determined by shape and size of 
cells, so that is how they get their names. Even 
thought these types occur very rarely, they 
represent the greatest diagnostic dillemas 
because of a high spectar of histopathological 
presentations (19).  
Stroma is mostly built out of loosely or 
poorly colagenized connective tissue with angio-
genesis, prominent in GISTs with higher malingnant 
potential. During tumor progression it often 
comes to acumulation of interstitial fluid, oedema 
and pseudocystic degeneration. If pseudocystic 
degeneration is dominant in tumor (more than 
50% of tumor mass) it conditions macroscopic cystic 
appearance. Fibrous hyaline changes, mixoid stromal 
changes, haemorrhagia, necrosis and pseudocystic 
degeneration can be seen with the growth of 
GIST. One type of fibrous-hyaline changes defines a 
special type of „GIST with skenoid fibers“, which 
is a prominent feature of interstitial GISTs. The 
so-called skenoid fibers are extracellular, thick, 
amorphic, dark-eosinophilic, irregular fibers, that 
remind us of yarn rolls or tree branches (19,21).  
 
Immunohistochemistry 
 
KIT protein (Figure 3b) and rarely CD34 
protein are expressed on the ICC cells Acta Medica Medianae 2010, Vol.49(3)                              Morphological and immunocytochemical characteristics of stromal… 
  61
membrane, so immunohistochemical detection of 
these receptors is a key point in GIST diagnostics. 
CD34 is at the same time a reliable marker for 
stromal neoangiogenesis of GISTs, which is an 
important link in malignant tumor progression 
(Figure 3c). KIT is expressed on differentiated 
ICC, mast cells and melanocytes as well on 
haematopoietic stem cells, pro-B and pro-T 
lymphocytes during development and on dendritic 
progenitor cells, erythroid cells, megakariocytes 
and myeloid line (5, 15, 24). In favor of GIST 
malignancy goes Intensive nuclear expression of 
ki-67 antigen, which detects all mithotic phases 
except of inactive phase (Figure 3d) (25). The 
most frequent used method in immunohisto-
chemistry is ABC method (A-avidin, B-biotine, C-
complex), which is based on a high affinity of 
avidin to biotine, as well as on the possibility of 
biotin binding to a secondary antibody which 
makes visualisation of wanted enzymes possible 
(Figure 3b, 3c, 3d). Research in the area of gene 
alterations is conducted with the aim to find 
adequate markers that would make early detection 
of GISTs possible as well as to warn of a relapse 
on time.So far, now it is known that most GISTs 
(95%) express transmembranous KIT receptors 
(CD117), CD34, vimentine, specific neurogenic 
and smooth muscle cell markers. A recent 
research showed that CD26 has a vital role as a 
tumor marker besides C-kit and CD34 markers 
that are already in the use in every day practise 
(26). 
 
Diagnostics and therapy 
 
Diagnosis of GISTs is usually made after 
laparotomy and formal pathological examinations, 
and the safest diagnostic methods represent CT 
and MRI because of the possibility of simultaneous 
examination of liver and peritoneum. The presence 
of GIST is rarely suspected before the operation, so 
diagnosis setting requires a high vigilance as well 
as knowledge of its visualization on radiograph. A 
study that included a high number of patients 
showed that the largest number had symptoms 
(GISTs in this group had an average size of 
6cm), 20% did not have symptoms (the average 
s i z e  o f  t u m o r s  w a s  2 c m )  a n d  1 0 %  o f  G I S T  
(average size of 1.5cm) are found only on 
autopsy.  
 
 
 
Figure 3a) Epitheloid-cell type: micromorphological characteristics. HEx250 3b) Epitheloid-cell type of GIST with 
intensive membrane activity. ABC: CD117x250. 3c) Striking angiogenessis in stroma. ABC: CD34x200.  3d) 
Intensive nuclear expression of ki-67 in rare cells. ABC: ki-67x300.. 
 
Table 1. Classification of GISTs according to the size of tumor and mithotic index (Ma CK et al, 2000) 
 
Risk group  Size  Mithosis/50hpf 
1.  A group of very low risk  <2 cm  <5 
2.  A group of low risk  2 – 5 cm  <5 
3.  A group of intermediate risk  <5 cm  6 – 10 cm 
or  5 – 10 cm  <5 
4.  A group of high risk  >5 cm  >5 
or  >10 cm  Any activity 
5.  A group of certain malignancy: patients with proven metastases at the time of diagnosis. Morphological and immunocytochemical characteristics of stromal…                                                                     Vuka Katić et al. 
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GISTs can reach extreme sizes before 
symptoms like hemorrhage and anemia occur. 
Symptoms mostly depend of the place of 
appearance and development and may include: 
dysphagia (esophagus), billiary obstruction (Vater’s 
ampulla), intususception of small intestine, deathly 
hemorrhage if they rupture into peritoneum, and etc. 
Percutaneous biopsy of GISTs should be avoided 
whenever possible, because it can cause tumor 
rupture that results in hemorrhage and dissemi-
nation (1,4) GISTs can be classified according to 
tumor size  and number of mitosis: group with 
very low risk, low risk, intermediate risk, high-
risk group and certain malignant group (Table 1) 
(19).  
Most frequently used therapy in the case of 
GISTs is resection and most of these tumors can 
be treated in that way, but recurrences occur in a 
high percent (20-40%). The most common compli-
cation that follows operation is distal methastasis 
in the liver (3,27,28). After the discovery of 
certain gene mutations that are a part of GIST 
etiology, imatinib was introduced into therapy of 
recurrent and unresectable GISTs. Imatinib selec-
tively inhibits a group of tyrosinkiase receptors, 
including KIT and PDGFRA. Adjuvant and neo-
adjuvant imatinib therapy is the most accepted in 
practice and it improves the prognosis of this 
disease, and it can be used in the case of 
advanced, recurrent and/or methastatic GIST. 
Despite great efficiency of this therapy and high 
security of its application, gastrointestinal and 
intraabdominal hemorrhage occurred in a few  
 
cases. Also, efficiency of this medication depends 
on a genotype that lies in the etiology of GIST as 
well as consequent changes of receptor functions 
(29). Sunitinib has the effect on imatinib resistant 
GISTs (15% of cases), but it also showed resistance 
to certain genotypes of GISTs (12,30). Studies 
on the impact of sunitinb on the initial stages of 
the disease are currently being conducted (12). 
Scientists hope that it will soon come to the 
discovery of new medications that would not 
show resistance (31). While pharmaceutical industry 
tries to find new target molecules for a safer 
method of treatment, the tendency of starting 
genetic therapy also exists (3,4,28,32,33). Imatinib 
and sunitinib are gaining in importance especially 
due to the fact that microscopic stages of tumors 
are discovered as well as inoperative stages of 
tumors in which therapy with medications is the 
only choice for now (24). 
 
Conclusion 
 
GISTs are heterogeneous group of mesen-
chimal tumors with moody clinical course. Because 
of heterogeneous cellularity, histological structure, 
mitotic activity and polymorphic angiogenesis, it 
is important to analyze numerous cutt-outs from 
the tumor as well as from the resection edges. 
Histological method is a “golden standard” of 
GIST diagnosis. For definite diagnosis, immuno-
histochemical tests are crucial: CD117 and/or 
CD34, smooth muscle cell actins, desmins, S-100 
protein, vimentine and ki-67. 
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MORFOLOŠKE I IMUNOCITOHEMIJSKE KARAKTERISTIKE 
GASTROINTESTINALNIH STROMALNIH TUMORA 
 
Vuka Katić, Boris Đinđić, Vesna Živković, Danica Marković, Bojana Marković- Živković, Ivan Ilić i 
Dušan Mihajlović 
 
 
Gastrointestinalni stromalni tumori (GISTomi) su najčešći mezenhimni tumori 
gastrointestinalnog trakta i karakterišu se izuzetnim šarenilom u kliničkim, histopatološkim 
i genetskim osobinama. Smatra se da svi GISTomi imaju maligni potencijal. Etiološki 
faktori koji izazivaju GISTome nisu jasno izdvojeni, a genetsku osnovu je teško odrediti jer 
su uglavnom sporadični. Međutim, otkrivene su izvesne genetske i citogenetske aberacije 
k o j e  s e  m o g u  s m a t r a t i  o d g o v o r n i m  z a  n a stanak GISToma. Makroskopska slika je 
polimorfna, ali se najčešće javljaju u vidu velike, pečurkaste intraluminalne, jasno 
ograničene pseudoinkapsulisane submukozne mase. Histomorfologija ovih tumora 
pokazuje širok spektar strukturnih i celularnih varijacija. Najčešće su građeni od 
vretenastih ćelija (60-70% slučajeva), ređe od epiteloidnih (oko 30% slučajeva), i veoma 
retko od mešovitih i prelaznih (intermedijarnih). Stroma je pretežno sastavljena od 
rastresitog ili slabo kolagenizovanog veziva sa neoaniogenezom, upadljivom kod GISToma 
sa većim malignim potencijalom. Većina GISToma (95%) eksprimira transmembranske 
receptore KIT (CD 117), CD34, vimentin, specifične neurogene i glatko-mišićne markere. 
Najuspešnije terapije GISToma su: hirurška resekcija, terapija imatinibom i sunitinibom 
(blokatori tirozin kinaznih receptora). Širom sveta se sprovode istraživanja koja bi 
omogućila pronalaženje novih i efikasnijih lekova koji bi sprečavali rezistentnost. Acta 
Medica Medianae 2010;49(3):58-64. 
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